ActoPlus Met

See also: Generic ActoPlus Met XR

ActoPlus Met is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):

ACTOPLUS MET (metformin hydrochloride; pioglitazone hydrochloride - tablet; oral)

• 
  Manufacturer: TAKEDA GLOBAL
  
  Approval date: August 29, 2005
  
  Strength(s): 500MG;EQ 15MG BASE ^[AB], 850MG;EQ 15MG BASE ^[RLD][AB]

Has a generic version of ActoPlus Met been approved?

A generic version of ActoPlus Met has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ActoPlus Met and have been approved by the FDA:

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet; oral)

• 
  Manufacturer: MYLAN
  
  Approval date: February 25, 2011
  
  Strength(s): 500MG;EQ 15MG BASE ^[AB], 850MG;EQ 15MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition
  Patent 5,965,584
  Issued: October 12, 1999
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical composition
  Patent 6,166,042
  Issued: December 26, 2000
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  



• 
  Pharmaceutical composition
  Patent 6,166,043
  Issued: December 26, 2000
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  



• 
  Pharmaceutical composition
  Patent 6,172,090
  Issued: January 9, 2001
  Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
  Assignee(s): Takeda Chemical Industries, Ltd.
  Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
  
  

See also...

• Actoplus Met Consumer Information (Drugs.com)
• Actoplus Met Consumer Information (Wolters Kluwer)
• Actoplus Met Consumer Information (Cerner Multum)
• Actoplus Met Advanced Consumer Information (Micromedex)
• Metformin Extended-Release/Pioglitazone Consumer Information (Wolters Kluwer)
• Metformin/Pioglitazone Consumer Information (Wolters Kluwer)
• Pioglitazone/Metformin Consumer Information (Wolters Kluwer)
• Pioglitazone/Metformin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Metformin and pioglitazone Consumer Information (Cerner Multum)
• Metformin and pioglitazone Advanced Consumer Information (Micromedex)
• Pioglitazone and metformin Advanced Consumer Information (Micromedex)